ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "autoimmune diseases"

  • Abstract Number: PP09 • 2018 ACR/ARHP Annual Meeting

    Improved Quality of Life and Decreased Symptoms of Lupus with Diet, Exercise, and Functional Medicine

    Marisa Zeppieri-Caruana, Lupus Chick, New York, NY

    Background/Diagnosis: Like most people who live with a chronic illness and/or autoimmune disease, my story started long before I realized. Symptoms came and went throughout…
  • Abstract Number: PP10 • 2018 ACR/ARHP Annual Meeting

    Using a Mobile App to Facilitate Patient-Doctor Discussions to Make Informed Decisions Regarding ‘Painsomnia’

    Shelley Fritz1, Kristine Carandang2 and Dawn Gibson3, 1ArthritisPower Patient Partner: CreakyJoints/Global Healthy Living Foundation, Tampa, FL, 2Chan Division of Occupational Science & Occupational Therapy, University of Southern California, Los Angeles, CA, 3Founder #SpoonieChat; CreakyJoints/Global Healthy Living Foundation Patient Partner, Upper Nyack, NY

    Background/Diagnosis: As a patient with AS, Dawn founded #SpoonieChat to provide a space on twitter for people living with chronic diseases to support each other.…
  • Abstract Number: 9 • 2018 ACR/ARHP Annual Meeting

    Integration of Cytokine Profiles with Distinct B-Cell Functions Reveals a Specific Micro-Environmental Framework in Autoimmune Diseases

    Quentin Simon1, Alexis Grasseau2, Bénédicte Rouvière2, Laetitia Le Pottier2, Divi Cornec3, Maria Orietta Borghi4, Rocio Aguilar Quesada5, Yves Renaudineau2,6, Marta Alarcón-Riquelme7, Jacques-Olivier Pers1 and Sophie Hillion2,6, 1U1227, Université de Brest, Inserm, Labex IGO, CHU de Brest, Brest, France, 2U1227, Lymphocytes B et Autoimmunité, Université de Brest, Inserm, Brest, France, 3Hopital La Cavale Blanche, Brest, France, 4University of Milan, IRCCS Istituto Auxologico Italiano, Milan, Italy, 5Biobanco Del Sistema Sanitario Publico de Andalucía, Sevilla, Spain, 6CHU de Brest, Brest, France, 7Medical Genomics, Center for Genomics and Oncological Research (GENYO), Granada, Spain

    Background/Purpose: The functional duality of B cells is central to balance immune homeostasis by regulating or promoting the immune response. However, the mechanisms by which…
  • Abstract Number: 126 • 2018 ACR/ARHP Annual Meeting

    Direct Interaction between Autoreactive B Cells and Endothelial Colony Forming Cells Induces Cytokine Production from B Cells through B Cell Receptor and IL-6-JAK2-STAT3 Signaling Pathway, Suppressing Proliferation of Endothelial Colony Forming Cells in Systemic Sclerosis

    Takemichi Fukasawa1, Ayumi Yoshizaki1, Satoshi Ebata1, Kouki Nakamura1, Yoshihide Asano1, Yutaka Kazoe2, Kazuma Mawatari2, Takehiko Kitamori2 and Shinichi Sato1, 1Department of Dermatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, 2Department of Applied Chemistry, Graduate School of Engineering, The University of Tokyo, Tokyo, Japan

    Background/Purpose: Systemic sclerosis (SSc) is a connective tissue disorder that is characterized by fibrosis and vascular damage in the skin and other visceral organs, with…
  • Abstract Number: 843 • 2018 ACR/ARHP Annual Meeting

    Localization of the Voltage-Gated Sodium Channel 1.7 in Peripheral Monocytes Contributes to Activation of BAFF Signaling in Monocytes of Patients with Primary Sjögren’s Syndrome

    Keiko Yoshimoto, Yumi Ikeda, Katsuya Suzuki and Tsutomu Takeuchi, Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan

    Background/Purpose: In our previous study, we have reported that IL-6 production was robustly increased in BAFF-stimulated peripheral monocytes of patients with primary Sjögren’s syndrome (pSS)…
  • Abstract Number: 1182 • 2018 ACR/ARHP Annual Meeting

    The Disproportionate High Risk of Re-Fracture after Osteoporotic Treatment in Patients with Autoimmune Diseases

    Wen-Nan Huang1, Yi-Ming Chen1, Wei-Ting Hung2, Yu-Wan Liao3 and Yi-Hsing Chen1, 1Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan, 2Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan, 3Taichung Veterans General Hospital, Taichung, Taiwan

    Background/Purpose: Patients with autoimmune diseases are associated with an increased risk of osteoporotic fracture. Anti-osteoporotic treatment could diminish re-fracture rates in post-menopause women. However, treatment…
  • Abstract Number: 1584 • 2018 ACR/ARHP Annual Meeting

    Evaluation of the Performance of the 2016 American College of Rheumatology-European League Against Rheumatism (Acr-Eular) Classification Criteria for Primary Sjogren`S Syndrome in Different Centers of Argentina

    Hugo Najera1, Marta Mamani2, Anastasia Secco1, Fernando Melo3, Cristian Troitiño4, Felix Romanini Sr.2, Emmanuel Guerra2, Antonio Catalan Pellet5, Silvia Beatriz Papasidero6, Rodrigo Aguila Maldonado7, Mercedes Garcia7, Mariano Rivero8, Juan Carlos Barreira9, ivan remolina10, A. perdomo11, quevedo mayorga10, M.J. santacruz12 and j demarchi10, 1Rheumatology Section, Hospital Bernardino Rivadavia, CABA, Argentina, 2Hospital Bernardino Rivadavia, Buenos Aires, Argentina, 3Rheumatology Department, Hospital Bernardino Rivadavia, Buenos Aires, Argentina, 4Reumatologia, Hospital Bernardino Rivadavia, CAPITAL FEDERAL, Argentina, 5Rheumatology, Hospital Bernardino Rivadavia, Buenos Aires, Argentina, 6Rheumatology Section, Hospital General de Agudos Dr. Enrique Tornú, Argentina, Buenos Aires, Argentina, 7Rheumatology, HIGA General San Martin La Plata, La Plata, Argentina, 8Rheumatology, Consultorios Externos Vacarezza,Alberdi,Pcia Buenos Aires, Pcia Buenos Aires, Argentina, 9Rheumatology Unit, Hospital Británico, Buenos Aires, Buenos Aires, Argentina, 10hospital britanico, Buenos Aires, Argentina, 11hospital nuestra señora de la merced, alberti, Argentina, 12hospital tornu, Buenos Aires, Argentina

    Background/Purpose: Primary Sjögren`s Syndrome (pSS) is a multisystemic, autoimmunity disease, characterized mainly by the hypofunction of the salivary and lacrimal glands, however the clinical spectrum…
  • Abstract Number: 1771 • 2018 ACR/ARHP Annual Meeting

    Long-Term Survival of Renal Transplantation in Rapidly Progressive Glomerulonephritis (RPGN). Study of 43 Cases from a Single Center

    Belén Atienza-Mateo1, Lara Sánchez-Bilbao1, José Luis Martín-Varillas1, Marina de Cos-Gómez2, Íñigo González-Mazón1, Diana Prieto Peña3, Monica Calderón Goercke3, Emilio Rodrigo Calabia2, Juan Carlos Ruiz San Millán2, Miguel Angel González-Gay1 and Ricardo Blanco4, 1Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 2Nephrology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 3Rheumatology, Rheumatology. Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 4Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain

    Background/Purpose: Rapidly Progressive Glomerulonephritis (RPGN) is characterized histology by presence of crescents and clinically by rapid and severe decline in kidney function. Thus, it may…
  • Abstract Number: 1002 • 2017 ACR/ARHP Annual Meeting

    Survival and Years of Potential Life Lost in Connective Tissue Disease and Vasculitis; Data from the Norwegian Connective Tissue Diseases and Vasculitis Registry (NOSVAR)

    Torhild Garen1, Karoline Lerang1, Anna Maria Hoffmann-Vold2, Helena Andersson1, Øyvind Midtvedt1, Karin Kilian1, Ragnar Gunnarsson1, Birgir Gudbrandsson1, Gudrun Norby1, Oyvind Molberg2 and Øyvind Palm1, 1Department of Rheumatology, Oslo University Hospital, Oslo, Norway, OSLO, Norway, 2Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway

    Background/Purpose: Survival is decreased in patients with connective tissue diseases (CTDs) and vasculitis, however few studies have compared the mortality between the specific diseases prospectively…
  • Abstract Number: 2121 • 2017 ACR/ARHP Annual Meeting

    Autoantibodies As Biomarkers for the Identification of Pre-Clinical Stages of Autoimmune Diseases: Demonstration of Inflammatory and Fibrotic Activity in the Liver of Asymptomatic and Biochemically Normal Individuals with Anti-Mitochondria Antibodies

    Danielle Baldo1, Alessandra Dellavance1, Maria Lucia Ferraz2 and Luis Eduardo C. Andrade3,4, 1Research and Development Department, Fleury Medicine and Health Laboratories, São Paulo, Brazil, 2Gastroenterology Division, Escola Paulista de Medicina, Universidade Federal de Sao Paulo, Sao Paulo, Brazil, 3Rheumatology Division, Universidade Federal de São Paulo, São Paulo, Brazil, 4Immunology Division, Fleury Medicine and Health, São Paulo, Brazil

    Background/Purpose: Circulating autoantibodies precede clinical onset of several autoimmune diseases. The characteristics of the so-called pre-clinical stage of autoimmune diseases are poorly understood. Anti-mitochondria autoantibodies…
  • Abstract Number: 1023 • 2017 ACR/ARHP Annual Meeting

    The Autoimmune Discovery Ichip Distinguishes Healthy Individuals (HC) from Those with SLE, Rheumatoid Arthritis (RA), Scleroderma (SSc), Sjogren’s Syndrome (SS), and the Anti-Phospholipid Syndrome (APS)

    Chaim Putterman1, Armando Gabrielli2, Alexandra Balbir-Gurman3, Pennina Safer4, Keren Jakobi-Brook4, Rachel Sorek4, Ilana Gluzman4, Steve Wallace5 and Irun R. Cohen4,6, 1Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, USA, Bronx, NY, 2Istituto di Clinica Medica dell'Università di Ancona, Ancona, Italy, Ancona, Italy, 3Rheumatology Unit, Rambam Health Care Campus, Rappaport Faculty of Medicine, Technion, Haifa, Israel, Haifa, Israel, 4ImmunArray Ltd., Rehovot, Israel, Rehovot, Israel, 5ImmunArray Inc., VA, USA, Richmond, VA, 6Weizmann Institute of Science, Rehovot, Israel, Rehovot, Israel

    Background/Purpose: Current serological tests are not sufficiently accurate in differentiating between HC and those with autoimmune rheumatic diseases. We developed the iCHIP antigen microarray to…
  • Abstract Number: 2128 • 2017 ACR/ARHP Annual Meeting

    A Systematic Review of the Management of Patients with Preexisting Rheumatologic Diseases Receiving Checkpoint Inhibitors for Cancer

    Noha Abdel-Wahab1,2, Mohsin Shah1, Maria A. Lopez-Olivo1 and Maria Suarez-Almazor1, 1Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, 2Rheumatology and Rehabilitation Department, Assiut University Hospitals, Assiut, Egypt, Assiut, Egypt

    Background/Purpose: The incidence and management of rheumatologic immune-related adverse events (irAEs) as a consequence of the checkpoint inhibitor (CPI) therapy in patients with cancer has…
  • Abstract Number: 1064 • 2017 ACR/ARHP Annual Meeting

    Characterization of Human Tolerogenic Dendritic Cells Generated with Protein Kinase C Inhibitor and Induction from Patients with Autoimmune Diseases

    Hitoshi Hasegawa1, Takuya Matsumoto1, Endy Adnan2, Jun Ishizaki1, Koichiro Suemori1 and Masaki Yasukawa1, 1Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine, Ehime, Japan, 2Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine, Ehime, Japan

    Background/Purpose: Tolerogenic dendritic cells (tDCs) are a promising therapeutic tool for specific induction of immunological tolerance. Human tDCs can be generated ex vivo using various…
  • Abstract Number: 2142 • 2017 ACR/ARHP Annual Meeting

    Autoantibodies Recognizing Cytosolic 5’-Nucleotidase 1A Are Associated with More Severe Disease in Patients with Juvenile Myositis

    Richard Yeker1, Iago Pinal-Fernandez2, Takayuki Kishi3, Ira N. Targoff4, Frederick W Miller3, Lisa G Rider3 and Andrew Mammen5, 1National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 2NIAMS, NIH, Bethesda, MD, 3Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, 4VA Medical Center, University of Oklahoma Health Sciences Center, Oklahoma Medical Research Foundation, Oklahoma City, OK, 5Muscle Diseases Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases. National Institutes of Health, Bethesda, MD

    Background/Purpose: Autoantibodies recognizing cytosolic 5’-nucleotidase 1A (NT5C1A) are present in the sera of adults with myositis and other autoimmune diseases. They are especially prevalent in…
  • Abstract Number: 1068 • 2017 ACR/ARHP Annual Meeting

    Impact of TNF Antagonist Treatment on the Gut Microbiome In Vivo

    Odile Gabay1, Jonathan Vicenty2, Grant Wunderlin3, Linda Tiffany2, Wells Wu4, Vahan Simonyan5 and Kathleen A Clouse6, 1Office of Biotechnology Products /Center for Drug Evaluation and Research DBRRI, U.S. Food and Drug Administration, Silver Spring, MD, 2Office of Biotechnology Products, Center for Drug Evaluation and Research, DBRRI, U.S. Food and Drug Administration, Silver Spring, MD, 3Center for Drug Evaluation and Research CDER DBRRI, U.S. Food and Drug Administration, Silver Spring, MD, 4Center for Biologic Evaluation and Research OMPT, U.S. Food and Drug Administration, Silver Spring, MD, 5Center for Biologic Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, 6Office of Biotechnology Products /Center for Drug Evaluation and Research,DBRRI, U.S. Food and Drug Administration, Silver Spring, MD

    Background/Purpose: Auto-immune diseases are in constant progression in the US. Biologic therapeutics have been used successfully to treat these diseases, but have presented some unique…
  • « Previous Page
  • 1
  • …
  • 70
  • 71
  • 72
  • 73
  • 74
  • …
  • 80
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology